<DOC>
	<DOCNO>NCT00705211</DOCNO>
	<brief_summary>This study non-interventional ( observational ) study Japan confirm safety efficacy Zetia administer alone combination lipid-lowering drug daily medical practice throughout 52-week period . It conduct post-approval commitment , accordance Ministry Health , Labour Welfare 's guideline Good Post-marketing Study Practice . Post-marketing survey consider applicable clinical trial thus result survey post conclusion . The result submit public health official require applicable national international law .</brief_summary>
	<brief_title>A 52-week Post-marketing , Observational Study Confirm Safety Efficacy Zetia Alone Combination With Other Lipid-lowering Drugs Japanese Subjects With Hypercholesterolemia ( Study P05245 )</brief_title>
	<detailed_description>The population select 200 institution Japan .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Hypolipidemic Agents</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects hypercholesterolemia , familial hypercholesterolemia , homozygous sitosterolemia consider study . Zetia monotherapy patient must treat Zetia alone . Zetia combination therapy patient must treat Zetia combination lipidlowering drug hypercholesterolemia . Patients history hypersensitivity ingredient Zetia Patients serious hepatic function disorder treat Zetia combination HMGCoA reductase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>